ClinicalTrials.gg
CompletedNCT01037348REPAIRUpdated Apr 19, 2016

Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen

A Phase 2 interventional study of ranibizumab 0.5mg in Choroidal Neovascularisation, sponsored by Novartis. Completed at 12 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-19.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
22nd of 45
65 · median 62
Started
2010
with 4 others
Phase 2
10 of 45
none open now
Registered
21st of 45
by date
Lead sponsor
5 of 45
Novartis

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 22nd largest by enrollment, is one of 5 that started in 2010, is one of 10 in phase 2, and was the 21st registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

This study is designed to provide efficacy and safety data in patients with choroidal neovascularisation (CNV) secondary to myopia using an individualized as-needed (PRN) dosing schedule. Eligible patients who have provided written agreement to take part in the study will receive an intravitreal (into the study eye) injection of ranibizumab 0.5mg. Following eye examinations and tests at monthly clinic visits, the study doctor will repeat the injections on a monthly basis as required for an additional 11 months, in accordance with specified retreatment criteria.

Patients will be in the study for approximately 12 months and will visit the hospital clinic 14 times over that period. The main assessments will include visual acuity tests, eye examinations, optical coherence tomography (OCT) to assess retinal thickness, fundus photography and fluorescein angiography (FA), measurement of intraocular pressure, blood pressure and pulse measurements and completion of health-related questionnaires'.

03

Conditions studied

  • Choroidal Neovascularisation

Keywords

  • Choroidal Neovascularisation
  • Pathological Myopia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients of any race, aged 18 years or older
  • Diagnosis of active primary or recurrent subfoveal or juxtafoveal CNV secondary to PM
  • Diagnosis of high myopia of at least -6 dioptres in the study eye spherical equivalent. For subjects who have undergone prior refractive or cataract surgery in the study eye, the preoperative refractive error in the study eye must have been at least -6 dioptres
  • Patients who have a BCVA score between 78 and 24 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS)-like grading charts (approximately 6/9 - 6/96 Snellen equivalent)
  • Patients must give fully and be willing and able to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • History of any surgical intervention in the study eye within two months preceding screening
  • Previous macular laser photocoagulation, treatment with intravitreal , verteporfin with photodynamic therapy (Visudyne®) or anti-VEGF agents ranibizumab, bevacizumab or pegaptanib sodium (Macugen®) in the study eye
  • Previous treatment with intravenously administered bevacizumab (Avastin®)
  • Prior treatment in the study eye with external-beam radiation therapy, vitrectomy, or transpupillary thermotherapy
  • History of to any of the study drugs or to drugs of similar chemical classes
  • History of allergic reaction to fluorescein
  • Concurrent use of systemic anti-VEGF agents

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    ranibizumab 0.5mg

    Drug: ranibizumab 0.5mg

Interventions

06

What researchers measure

Primary outcomes

  1. The difference from baseline in mean Best Corrected Visual Acuity (BCVA)

    Time frame: 12 months

Secondary outcomes

  1. Mean change in BCVA from baseline

    Time frame: 6 months

  2. Mean change in Central retinal Thickness (CRT) from baseline

    Time frame: 6 and 12 months

  3. Percentage of patients gaining ≥ 15 letters

    Time frame: 12 months

  4. Change in lesion size and morphology from baseline

    Time frame: 6 and 12 months

  5. Time to the first retreatment and the total number of treatments

    Time frame: 12 Months

07

Study locations

12 sites
  • Novartis Investigative Site
    Bristol, BS1 2LX, United Kingdom
  • Novartis Investigational Site
    City of London, EC1V 2PD, United Kingdom
  • Novartis Investigative Site
    City of London, NW1 5YE, United Kingdom
  • Novartis Investigative Site
    City of London, SE5 9RS, United Kingdom
  • Novartis Investigative Site
    Frimley, GU16 7UJ, United Kingdom
  • Novartis Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • Novartis Investigative Site
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG5 1PG, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
  • Novartis Investigative Site
    Torquay, TQ2 7AA, United Kingdom
  • Novartis Investigative Site
    Wolverhampton, WV10 0QP, United Kingdom
  • Novartis Investigative Site
    York, YO31 8HE, United Kingdom
08

References and documents

Publications

  • Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Osoba O, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Andrews C, Brittain C, Osborne A, Yang Y. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013 Sep;120(9):1944-5.e1. doi: 10.1016/j.ophtha.2013.06.010. No abstract available. PubMed 24001532 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2009
First posted
Dec 23, 2009
Start
Jan 2010
Primary completionActual
May 2012
CompletionActual
May 2012
Last update
Apr 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01037348
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Dec 23, 2009
Start date
Jan 2010
Primary completion
May 2012
Completion
May 2012
Last update
Apr 19, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion